BMRN:NSD-BioMarin Pharmaceutical Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 78.18

Change

-0.94 (-1.19)%

Market Cap

USD 14.64B

Volume

0.93M

Avg Analyst Target

USD 115.29 (+47.46%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BioMarin Pharmaceutical Inc (BMRN) Stock Analysis:
Based on the BioMarin Pharmaceutical Inc stock forecasts from 12 analysts, the average analyst target price for BioMarin Pharmaceutical Inc is USD 115.29 over the next 12 months. BioMarin Pharmaceutical Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BioMarin Pharmaceutical Inc is Neutral, which is based on 9 positive signals and 8 negative signals. At the last closing, BioMarin Pharmaceutical Inc’s stock price was USD 78.18. BioMarin Pharmaceutical Inc’s stock price has changed by +3.30% over the past week, -3.70% over the past month and +0.66% over the last year.

About

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-8.36 (-1.25%)

USD72.27B 9.28 6.88
VRTX Vertex Pharmaceuticals Incorpo..

-9.49 (-3.62%)

USD66.97B 29.06 18.23
MRNA Moderna Inc

-4.57 (-3.21%)

USD54.20B 4.82 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-2.74 (-1.71%)

USD36.74B 3.67 1.75
RPRX Royalty Pharma plc

-0.85 (-2.06%)

USD27.88B 27.76 15.36
SGEN Seagen Inc

-3.55 (-2.42%)

USD26.98B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

-0.81 (-2.66%)

USD19.31B 46.16 5.06
INCY Incyte Corporation

-2.12 (-2.81%)

USD16.73B 17.68 22.08

ETFs Containing BMRN

Symbol Name Weight Mer Price(Change) Market Cap
BIOT:LSE L&G Pharma Breakthrough U.. 4.04 % 0.75 %

N/A

USD8.18M
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+1.58 (+5.53%)

USD8.57M
EASI Amplify EASI Tactical Gro.. 0.00 % 0.81 %

N/A

USD0.01B
FBT:LSE First Trust Global Funds .. 0.00 % 0.60 %

-8.30 (-0.63%)

N/A
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.79 %

N/A

N/A
BIOT Biotech Acquisition Compa.. 0.00 % 0.75 %

+0.01 (+0.05%)

N/A
BIGT:LSE Legal & General UCITS ETF.. 0.00 % 0.49 %

-2.70 (-0.31%)

USD0.04B
GNOM Global X Genomics & Biote.. 0.00 % 0.50 %

-0.48 (-3.99%)

USD0.13B
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

-0.56 (-2.11%)

USD0.02B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

-4.19 (-3.09%)

USD1.32B
FCVT First Trust SSI Strategic.. 0.00 % 0.95 %

-0.50 (-1.49%)

USD0.21B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

-1.36 (-4.26%)

USD0.06B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.07 %

+7.79 (+14.80%)

USD0.07B
FHH:CA First Trust AlphaDEX U.S... 0.00 % 0.77 %

-0.69 (-1.85%)

USD0.02B
FBTU:LSE First Trust Global Funds .. 0.00 % 0.60 %

-0.19 (-1.16%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.51% 87% B+ 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.51% 87% B+ 61% D-
Trailing 12 Months  
Capital Gain 2.30% 92% A- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.30% 92% A- 83% B
Trailing 5 Years  
Capital Gain -12.38% 67% D+ 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.38% 67% D+ 32% F
Average Annual (5 Year Horizon)  
Capital Gain 0.00% 47% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.00% 47% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 18.14% 98% A+ 73% C
Risk Adjusted Return 0.02% 47% F 36% F
Market Capitalization 14.64B 98% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 368.00 5% F 4% F
Price/Book Ratio 3.27 25% F 25% F
Price / Cash Flow Ratio 48.06 1% F 6% F
EV/EBITDA 91.37 3% F 8% F
Management Effectiveness  
Return on Equity 0.92% 92% A- 50% F
Return on Invested Capital -1.35% 88% B+ 47% F
Return on Assets -0.74% 92% A- 45% F
Debt to Equity Ratio 25.27% 47% F 56% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 8.95 24% F 12% F
Short Percent 6.17% 39% F 28% F
Beta 0.49 85% B 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector